HomeCompareEPIX vs PLD

EPIX vs PLD: Dividend Comparison 2026

EPIX yields 840.47% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPIX wins by $4215405.78M in total portfolio value
10 years
EPIX
EPIX
● Live price
840.47%
Share price
$0.20
Annual div
$1.69
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4215412.28M
Annual income
$3,415,908,279,597.25
Full EPIX calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — EPIX vs PLD

📍 EPIX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEPIXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EPIX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EPIX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EPIX
Annual income on $10K today (after 15% tax)
$71,440.13/yr
After 10yr DRIP, annual income (after tax)
$2,903,522,037,657.66/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, EPIX beats the other by $2,903,517,569,686.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EPIX + PLD for your $10,000?

EPIX: 50%PLD: 50%
100% PLD50/50100% EPIX
Portfolio after 10yr
$2107709.39M
Annual income
$1,707,956,768,016.71/yr
Blended yield
81.03%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

EPIX
Analyst Ratings
2
Buy
3
Hold
Consensus: Hold
Price Target
$9.50
+4621.7% upside vs current
Range: $2.00 — $17.00
Altman Z
1.1
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EPIX buys
0
PLD buys
0
No recent congressional trades found for EPIX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEPIXPLD
Forward yield840.47%3.18%
Annual dividend / share$1.69$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$4215412.28M$6.50M
Annual income after 10y$3,415,908,279,597.25$5,256,436.18
Total dividends collected$4152700.41M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$9.50$136.00

Year-by-year: EPIX vs PLD ($10,000, DRIP)

YearEPIX PortfolioEPIX Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$94,747$84,047.22$11,255$555.24+$83.5KEPIX
2$845,608$744,228.02$13,062$1,018.59+$832.5KEPIX
3$7,112,413$6,207,612.95$15,903$1,926.67+$7.10MEPIX
4$56,406,815$48,796,533.54$20,839$3,823.32+$56.39MEPIX
5$422,031,389$361,676,096.60$30,464$8,166.08+$422.00MEPIX
6$2,980,575,750$2,529,002,163.86$52,054$19,457.30+$2980.52MEPIX
7$19,881,694,862$16,692,478,809.61$109,886$54,188.93+$19881.58MEPIX
8$125,334,964,899$104,061,551,396.31$304,030$186,451.18+$125334.66MEPIX
9$747,200,001,618$613,091,589,175.98$1,166,125$840,813.32+$747198.84MEPIX
10$4,215,412,281,328$3,415,908,279,597.25$6,504,190$5,256,436.18+$4215405.78MEPIX

EPIX vs PLD: Complete Analysis 2026

EPIXStock

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Full EPIX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this EPIX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EPIX vs SCHDEPIX vs JEPIEPIX vs OEPIX vs KOEPIX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.